Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio Submissions to Health Canada planned for 2025 MONTREAL, Dec. 04, 2024 (GLOBE...
MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
New financing replaces existing credit facility to optimize Company’s capital structureFavorable interest rates and amortization schedules to free up approximately $19 million in cash in 2025 to...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
Q3 revenue of $22.6 million represents +8% growth year-over-yearPositive net income of $3.1 million or 6 cents per share, and Adjusted EBITDA1 of $7.2 million Fiscal 2024 guidance revised to...
MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.51 | 25.1231527094 | 2.03 | 2.57 | 1.97 | 62005 | 2.21905036 | CS |
| 4 | 0.84 | 49.4117647059 | 1.7 | 2.57 | 1.6 | 54220 | 2.01465987 | CS |
| 12 | 0.91 | 55.8282208589 | 1.63 | 2.57 | 1.6 | 46956 | 1.8331391 | CS |
| 26 | 0.77 | 43.5028248588 | 1.77 | 2.57 | 1.59 | 34390 | 1.84094766 | CS |
| 52 | 0.41 | 19.2488262911 | 2.13 | 3.43 | 1.59 | 31908 | 1.9991804 | CS |
| 156 | -13.74 | -84.398034398 | 16.28 | 16.68 | 1.22 | 35951 | 4.54244731 | CS |
| 260 | -12.58 | -83.2010582011 | 15.12 | 22.4 | 1.22 | 66697 | 10.76878765 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
